• 330
  • 28
  • Favorite

F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients

Benzinga2021-08-12

  • F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.
  • The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).
  • FS118 is a bispecific antibody targeting LAG-3 and PD-L1.
  • In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.
  • F-Star ended the quarter with cash and cash equivalents of $81.6 million.
  • Price Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment28

  • Dbw
    ·2021-08-13
    Like and comment pls
    Reply
    Report
  • 1nu
    ·2021-08-13
    help me like and comment :)
    Reply
    Report
    Fold Replies
    • FunnyFun
      Ok
      2021-08-13
      Reply
      Report
    • Singman
      pls like too
      2021-08-13
      Reply
      Report
  • 保升龙
    ·2021-08-13
    Ok
    Reply
    Report
    Fold Replies
  • Syww
    ·2021-08-13
    [Strong] [Strong] 
    Reply
    Report
  • Sonson89
    ·2021-08-13
    K
    Reply
    Report
  • 飙高音
    ·2021-08-13
    Ok
    Reply
    Report
  • JimmyLZH
    ·2021-08-13
    ??
    Reply
    Report
  • xremy
    ·2021-08-13
    Another Big... Upupup.. 
    Reply
    Report
  • white_fangg
    ·2021-08-13
    Like and comment
    Reply
    Report
    Fold Replies
    • Pplymm
      Done. pls like back
      2021-08-13
      Reply
      Report
    • alexpee98
      yes babe
      2021-08-13
      Reply
      Report
  • pfudor
    ·2021-08-13
    Ok
    Reply
    Report
  • Andtendo
    ·2021-08-13
    Like and comment please
    Reply
    Report
    Fold Replies
    • Pplymm
      Done. pls like back
      2021-08-13
      Reply
      Report
  • lingnh
    ·2021-08-13
    Ok
    Reply
    Report
  • losty
    ·2021-08-13
    Like please
    Reply
    Report
    Fold Replies
  • liangwee888
    ·2021-08-13
    comment
    Reply
    Report
    Fold Replies
    • MamaProfit
      no comment
      2021-08-13
      Reply
      Report
  • PooYen
    ·2021-08-13
    Please like. Thanks  [Happy] [Happy] [Happy] 
    Reply
    Report
    Fold Replies
    • Pplymm
      Done. pls like back
      2021-08-13
      Reply
      Report
    • eddnesb
      like pls
      2021-08-13
      Reply
      Report
    • VenomJames
      Sure
      2021-08-13
      Reply
      Report
  • J90
    ·2021-08-13
    Help
    Reply
    Report
    Fold Replies
  • J90
    ·2021-08-13
    Yaaaa
    Reply
    Report
    Fold Replies
    • Xue91
      Yahhhh
      2021-08-13
      Reply
      Report
  • Andrew210782
    ·2021-08-13
    Like
    Reply
    Report
  • June_C
    ·2021-08-13
    Wiooo
    Reply
    Report
  • MoreNmore
    ·2021-08-13
    Like
    Reply
    Report
 
 
 
 

Most Discussed

 
 
 
 
 

7x24

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email:uservice@ttm.financial